Skip to main content

Table 2 Mutational profile of MLH1−/− derived cell lines using an in-house panel of cMS marker

From: In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters

cMS Marker

APC

Tmem60

Senp6

Phactr4

Aste1

Taf1b

Sdccag1

Rasal2

Lig4

Bend5

Supt16

C8a

Kcnma1

Rfc3

ERCC5

DNAJC2

IL1F9

Clock

Akt3

Spen

Frequency

Sample/Repeat

A8

A8

A11

A10

A8

A8

A11

A8

A9

A8

A8

T8

A10

A10

A9

A8

A10

T9

T8

A8

(n)

(%)

328

wt

−1/−2

wt

wt

wt/−1

wt/−1

wt

wt

wt/−1

wt

wt/−1

wt

wt/−1

wt/−1

wt

−1

−1

wt/−1

wt/−1

wt/−1

12/32

37.50

7450 T1 M1

wt/−1

wt

wt/−1

−1

wt

wt/−1

−1

wt/−1

−1

wt/−1/−2

−1

MSI

wt/−1

wt/−1

wt/−1

wt

−1

wt

wt/−1

wt/−1

16/32

50.00

  1. wt: wildtype; wt/−1: heterozygous mutation; −1: homozygous mutation